Print Page     Close Window     

Investor Home

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$157.32

 0.19 (0.12%)

08/17/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China - August 9, 2018
BEIJING, China and CAMBRIDGE, Mass., Aug. 9, 2018 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercia... Read More
BeiGene Reports Second Quarter 2018 Financial Results - August 9, 2018
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a co... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts
 

© 2016 BeiGene. All Rights Reserved.